“kymera-therapeutics” Archives

in
Entry Author Date Location
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs 09/24/20 Boston
Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More 08/28/20 National
Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More 08/21/20 National
Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts 08/20/20 National
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More 08/07/20 National
Kymera Therapeutics Unveils IPO Pitch for Protein Degradation 07/31/20 Boston
Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More 07/10/20 National
Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership 07/09/20 Boston
GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance 06/16/20 San Francisco
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More 03/13/20 National
Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic 03/12/20 Boston
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels 10/07/19 National
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes 09/03/19 Boston
Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More 07/19/19 National
Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance 06/04/19 Boston
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More 05/17/19 National
Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera 05/15/19 Boston
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More 11/16/18 National
Kymera Adds $65M in New Funding and Eyes First Clinical Test 11/13/18 Boston
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs 08/30/18 San Francisco
With $59M, Casma and Ex-Constellation CEO Take Aim at Cellular Trash 05/03/18 Boston
Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More 11/03/17 National
Page 1 of 1